Telix Pharmaceuticals Ltd — Director's Dealing 2019

Sep 16, 2019

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Telix Pharmaceuticals Limited ABN 85 616 620 369

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Oliver Buck
Date of last notice	15 November 2017 (Appendix 3X)

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect Interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Evo-partners GmbH of which Oliver Buck is a director and shareholder.
Date of change	17 September 2019
No. of securities held prior to change	1,057,500 fully paid ordinary shares. 495,000 unlisted share options with an exercise price of $0.85 per option and an expiry date of 14 October 2021, granted subsequent to shareholder approval at the EGM held 13 October 2017.
Class	Exercise of options to acquire fully paid ordinary shares.
Number acquired	164,835 fully paid ordinary shares (subject to ASX Mandatory Restriction until 15 November 2019).
Number disposed	Nil

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Options were exercised at an exercise price of $0.85c per option, for a total consideration of $140,110.
No. of securities held after change	1,222,335 fully paid ordinary shares. Of this amount, 164,835 fully paid ordinary shares are subject to ASX Mandatory Restriction until 15 November 2019. 330,165 unlisted share options with an exercise price of $0.85 per option and an expiry date of 14 October 2021, granted subsequent to shareholder approval at the EGM held 13 October 2017.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of options to acquire shares

Part 2 – Change of director’s interests in contracts – NOT APPLICABLE

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3